More specifically, the drug is indicated for ‘slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease.’

Leqembi has been proven to reduce the rate of disease progression and slow cognitive decline by selectively binding to amyloid beta (Aβ) aggregates, which are a known cause of Alzheimer's disease.

Due to such a lack of treatments for the disease, the desperation of the patients and their families has been indescribable. In addition to public petitions, the MFDS's Korea Orphan & Essential Drug Center has been inundated with inquiries on the date of Leqembi’s approval and supply in Korea.

However, the problem is the pri